894 / 1631
41
Investigator-assessed
PFS (primary endpoint)
*Stratified analysis; stratification factors: IPI score, number of planned chemotherapy cycles
R-CHOP,
n=712
G-CHOP,
n=706
Pts with event,
n (%)
215
(30.2)
201
(28.5)
1-yr PFS, %
79.8
81.6
2-yr PFS, %
71.3
73.4
3-yr PFS, %
66.9
69.6
HR (95% CI),
p-value*
0.92 (0.76, 1.11),
p=0.3868
Median follow-up: 29 months
Kaplan-Meier plot of investigator-assessed
PFS by treatment arm
No. of patients at risk
R-CHOP
G-CHOP
712
706
616
622
527
540
488
502
413
425
227
240
142
158
96
102
41
39
6
2
R-CHOP (n=712)
G-CHOP (n=706)
6 12 18 24 30 36 42 48 54
Time (months)
60
Probability
1.0
0.8
0.6
0.4
0.2
0
0
Vitolo et al ASH 2016 and J Clin Oncol. 2017 Nov 1;35(31):3529-3537